FacultyFaculty/Author Profile
Jane T. Gunnison

Jane T. Gunnison

Ropes & Gray LLP

New York City, NY, USA


Jane works with a wide range of biotechnology and pharmaceutical clients on strategic portfolio development and management, world-wide patent prosecution, opinions, search-based analyses including freedom to operate advice, USPTO interferences, foreign oppositions and IP diligence.

Jane provides advanced strategic advice to her clients, on patent matters in technologies including genomics, vaccines, transgenic animals, assays and high throughput genomics and proteomics systems, discovery genetics, diagnostics, personalized medicine, gene silencing and diverse biologics.
Jane has over 15 years of experience obtaining world-wide protection for antibodies.

Representative Clients and Matters

  • Jane represented Amgen (and previously we represented Abgenix) on a patent portfolio relating to the XENOMOUSE® technology, one of the most significant developments in the last quarter century in making available therapeutic antibodies for human therapy
  • Jane represents Eisai in intellectual property matters, including opinions, counseling, search-based analyses and patent prosecution


Honors & Awards


PLC Which Lawyer (2010-2011)

Memberships & Affiliations

  • American Bar Association
  • American Intellectual Property Law Association
  • New York State Bar Association

Presentations & Speeches

  • "Securing Patents for Antibodies Against a Backdrop of Heightened Patentability Requirements," 18th Forum On Biotech Patenting, Munich (March 2010)
  • "Securing Patents for Antibodies Against a Backdrop of Heightened Patentability Requirements," 17th Forum On Biotech Patenting, London (October 2009)
  • "Maximizing Patent Term Under 35 U.S.C. § 154," 7th Annual MAXIMIZING PHARMACEUTICAL PATENT LIFE CYCLES, Brand Name Master Class, New York (October 2009)
  • "Breaking Through the Challenges Associated with Antibody Patent Prosecution," 11th Advanced Forum On Biotech Patents, Boston (October 2009)
  • "The Narrowing Scope of Biotech Patent Claims: What Does It Mean for the Industry?" BIO International Conference, Atlanta (May 2009)
  • "Issues in Biotechnology Patenting: Are Prosecutors and Litigators on the Same Page and Can They Get There?" New York Biotechnology Association 18th Annual Meeting (April 2009)
  • "Maximizing Patent Term Under 35 U.S.C. § 154," 7th Annual MAXIMIZING PHARMACEUTICAL PATENT LIFE CYCLES, Brand Name Master Class, New York (October 2007)
  • "Maximizing Patent Term Under 35 U.S.C. § 154," 7th Annual MAXIMIZING PHARMACEUTICAL PATENT LIFE CYCLES, Brand Name Master Class, San Francisco (June 2007)
  • "Antibody Patentability," Advanced Forum On Biotech Patents, C5 Conference, Munich (April 2007)
  • "Patent Portfolio Management," Pharmaceutical/Biotech Industry Forum, New York (February 2007)
  • "Maximizing Patent Term Under 35 U.S.C. § 154," 7th Annual MAXIMIZING PHARMACEUTICAL PATENT LIFE CYCLES, Brand Name Master Class, New York (October 2006)
  • "Antibody Patentability," Advanced Forum On Biotech Patents, C5 Conference, London (September 2006)
  • "Maximizing Patent Term Under 35 U.S.C. § 154," 6th Annual MAXIMIZING PHARMACEUTICAL PATENT LIFE CYCLES, Brand Name Master Class, New York (October 2005)
  • "Antibody Patentability," 5th Advanced Forum on Biotech Patents, American Conference Institute, New York (September 2005)
  • "Integra v. Merck Safe Harbor Provisions," Advanced Forum On Biotech Patents, American Conference Institute, New York (January 2005)
  • "Patent Prosecution Basics," Patent Basics for the Non-Specialist, Practicing Law Institute (2005-present)
  • "Antibody Patentability," 4th Advanced Forum on Biotech Patents, American Conference Institute (December 2004)
  • "A Tactical And Practical Guide To FREEDOM TO OPERATE," American Conference Institute, New York (November 2003)
  • "PTO GUIDELINES FOR EXAMINATION UNDER § 102(e) IN VIEW OF AMERICAN INVENTORS PROTECTION ACT," Joint Patent Practice Seminar Connecticut, New Jersey, New York and Philadelphia Intellectual Property Law Associations, New York (May 2003)
  • "FOCUS ON RESEARCH TOOLS/METHOD PATENTS," Advanced Forum On Biotech Patents, American Conference Institute, New York and San Francisco (April and October 2003) (April 2004)
  • "CAN A PATENT APPLICATION HAVE TOO MUCH DISCLOSURE?" New York Biotechnology Association (February 2003)
  • "How to Protect Your Databases of Genomic and Proteomic Data: The US Perspective," EuroLegal Conference: Patenting your Genomic and Proteomic Inventions, London (July 2002)
Education
  • JD, Columbia University School of Law, Harlan Fiske Stone Scholar
  • MS (Biology), New York University
  • BA (Cell Biology), Smith College, with Honors

Bar Admissions

New York
U.S. Patent and Trademark Office

Courts

Supreme Court of the United States, 2005
U.S. Court of Appeals for the Federal Circuit, 2001
U.S. District Court for the Southern District of New York, 1994
U.S. District Court for the Eastern District of New York, 1994

Share
Email

  • FOLLOW PLI:
  • twitter
  • LinkedIn
  • GooglePlus
  • RSS

All Contents Copyright © 1996-2017 Practising Law Institute. Continuing Legal Education since 1933.

© 2017 PLI PRACTISING LAW INSTITUTE. All rights reserved. The PLI logo is a service mark of PLI.